Overcoming the Challenges of Gene Therapy

Scientists tackle AAV gene therapy hurdles, from enhancing efficiency to managing immunogenicity  to improve AAV gene therapy efficacy and safety.

Gene therapy is a beacon of hope for treating incurable genetic diseases, but most gene therapies rely on adeno-associated viral (AAV) vectors for their delivery. These viral carriers may trigger toxic immune responses and decrease gene therapy efficiency. In this seminar, four gene therapy experts will discuss the major hurdles of AAV-based gene therapy, including inefficient vector delivery, immunogenicity, and viral vector integration.

Topics to be covered

  • Minimizing post-organ transplant complications with gene therapy 
  • Addressing the immune response to gene therapy
  • Enhancing viral gene delivery and manufacturing using directed evolution and genetic selection
  • Preventing AAVs from integrating into the genome

Thursday, June 29th, 2023 | 1:30 PM - 4:00 PM Eastern Time
This seminar will be available to view live and on demand.


Dawn E. Bowles, PhD

Dawn Bowles, PhD

Assistant professor
Duke University

Samira Kiani, MD, PhD

Samira Kiani, MD, PhD

Associate Professor
University of Pittsburgh

David Schaffer, PhD

David Schaffer, PhD

Hubbard Howe Jr. Distinguished Professor
University of California at Berkeley

Weidong Xiao, PhD

Weidong Xiao, PhD

Indiana University

Supported by